Robyn A. Rourick

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

87

H-Index

1

About

Robyn A. Rourick is a leading figure in drug discovery and development, with a primary focus on absorption, distribution, metabolism, and excretion (ADME) sciences. Her major contributions center on revolutionizing early-stage drug screening through high-throughput automation, enabling rapid metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. Her seminal 2004 paper on this topic, which has garnered 87 citations, established foundational methodologies that accelerated lead optimization and reduced late-stage attrition in pharmaceutical pipelines. Rourick’s work has been instrumental in bridging the gap between combinatorial chemistry and preclinical safety, allowing researchers to assess drug-like properties earlier and more efficiently. Her achievements include advancing automated ADME assays that are now standard in the industry, significantly impacting how pharmaceutical companies prioritize compounds. By integrating robust, scalable screening platforms, she has helped shape modern drug discovery practices, making her a key contributor to the field’s evolution toward faster, more cost-effective development of safer therapeutics.

Research Focus

Key Achievements

1
H-Index
1
Papers
87
Total Citations
87
Avg Citations/Paper
🏆 Most Cited Paper
Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries
87 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago